GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Debt-to-Asset

Faron Pharmaceuticals Oy (LSE:FARN) Debt-to-Asset : 0.36 (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Debt-to-Asset?

Faron Pharmaceuticals Oy's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £3.20 Mil. Faron Pharmaceuticals Oy's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £7.57 Mil. Faron Pharmaceuticals Oy's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was £30.00 Mil. Faron Pharmaceuticals Oy's debt to asset for the quarter that ended in Jun. 2024 was 0.36.


Faron Pharmaceuticals Oy Debt-to-Asset Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Debt-to-Asset Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.39 0.27 1.18 1.28

Faron Pharmaceuticals Oy Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 1.18 1.05 1.28 0.36

Competitive Comparison of Faron Pharmaceuticals Oy's Debt-to-Asset

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Debt-to-Asset falls into.



Faron Pharmaceuticals Oy Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Faron Pharmaceuticals Oy's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Faron Pharmaceuticals Oy's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faron Pharmaceuticals Oy  (LSE:FARN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Faron Pharmaceuticals Oy Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy Headlines

No Headlines